Researchers Test NEt-3IB Eye Drops in Mice, Cutting Dry Eye Inflammation With Lower Pressure Risk
Updated
Updated · indonesiakini.id · Jun 1
Researchers Test NEt-3IB Eye Drops in Mice, Cutting Dry Eye Inflammation With Lower Pressure Risk
1 articles · Updated · indonesiakini.id · Jun 1
NEt-3IB eye drops reduced inflammation and protected the eye’s surface in a mouse study, pointing to a potential new treatment for dry eye disease.
The compound was developed as an alternative to steroid-based drops, which can work against inflammation but raise long-term risks such as glaucoma and cataracts.
Researchers said NEt-3IB caused a smaller increase in eye pressure than some existing steroid treatments, a key safety advantage for chronic use.
Dry eye disease is common—especially among older adults and women—and can cause redness, irritation, blurred vision and, in severe cases, surface damage that disrupts reading or driving.
Human trials are still needed before the treatment can be adopted clinically, leaving the findings as an early but promising step toward safer long-term care.
This breakthrough fixes dry eye in mice. What other chronic inflammatory diseases could this new approach revolutionize next?
Could this 'safer' dry eye drop's unique mechanism pose its own unknown long-term health risks?
Is a new super-drug the answer, or a band-aid for the screen-induced dry eye epidemic?